COVINGTON & BURLING LLP

Lobbying for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · Senate · $450,000.00 income · posted Apr 20, 2026

Bills named in this filing 14

S 43
Skinny Labels, Big Savings Act
HR 6485
Skinny Labels, Big Savings Act
S 2276
ETHIC Act
HR 3269
ETHIC Act
S 1414
Expedited Access to Biosimilars Act
S 1954
Biosimilar Red Tape Elimination Act
HR 5526
Biosimilar Red Tape Elimination Act
HR 7140
CLEAR Act
S 4098
Artificial Intelligence-Ready Data Act
S 1096
Preserve Access to Affordable Generics and Biosimilars Act
S 1040
Drug Competition Enhancement Act
S 4023
America’s Living Library Act
S 3788
CLEAR LABELS Act
S 5459
Biosimilars Access and Affordability Act

Lobbying activity 2

Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269).

Health Issues

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.